ストックスクリーナーアプリを入手
111.96
1.74%
1.91
プレマーケット:
111.90
-0.06
-0.05%
前日終値:
$110.05
開ける：
$110.24
24時間の取引高:
791.93K
Relative Volume:
1.15
時価総額：
$7.01B
収益：
$434.41M
当期純損益:
$-128.05M
株価収益率:
-53.06
EPS:
-2.11
ネットキャッシュフロー:
$-250.52M
1週間 パフォーマンス:
+9.17%
1か月 パフォーマンス:
+24.21%
6か月 パフォーマンス:
-2.62%
1年 パフォーマンス:
+38.14%
1日の値動き範囲:
$108.16
$112.52
1週間の範囲:
$103.67
$112.52
52週間の値動き範囲:
$72.24
$121.90
Blueprint Medicines Corp Stock (BPMC) Company Profile
名前
Blueprint Medicines Corp
セクター
電話
617-374-7580
住所
45 SIDNEY STREET, CAMBRIDGE, MA
BPMC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BPMC
Blueprint Medicines Corp
|
111.96 | 7.01B | 434.41M | -128.05M | -250.52M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-14 | 開始されました | JP Morgan | Overweight |
| 2024-10-24 | 開始されました | UBS | Neutral |
| 2024-05-14 | 開始されました | Stephens | Overweight |
| 2024-05-06 | アップグレード | Leerink Partners | Underperform → Market Perform |
| 2023-10-27 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-08-21 | 繰り返されました | Needham | Buy |
| 2023-07-31 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-06-05 | ダウングレード | SVB Securities | Market Perform → Underperform |
| 2023-01-03 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | 開始されました | Needham | Buy |
| 2022-11-02 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-09-14 | 開始されました | Berenberg | Buy |
| 2022-07-08 | 開始されました | Oppenheimer | Outperform |
| 2022-06-27 | 開始されました | Wells Fargo | Underweight |
| 2022-06-10 | ダウングレード | Citigroup | Neutral → Sell |
| 2022-06-01 | アップグレード | Jefferies | Hold → Buy |
| 2022-03-01 | 開始されました | Citigroup | Neutral |
| 2022-02-17 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-01-25 | アップグレード | Stifel | Hold → Buy |
| 2021-11-19 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-09-30 | 再開されました | Stifel | Hold |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-03-31 | 開始されました | Credit Suisse | Neutral |
| 2020-12-03 | 開始されました | Stifel | Hold |
| 2020-11-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-11-02 | ダウングレード | Jefferies | Buy → Hold |
| 2020-10-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-15 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-05 | 開始されました | Barclays | Equal Weight |
| 2020-03-17 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-28 | 開始されました | BMO Capital Markets | Market Perform |
| 2020-01-27 | 開始されました | BMO Capital Markets | Market Perform |
| 2019-11-06 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2019-10-22 | 開始されました | JMP Securities | Mkt Outperform |
| 2019-10-03 | 開始されました | H.C. Wainwright | Buy |
| 2019-09-12 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2019-08-29 | 開始されました | Piper Jaffray | Neutral |
| 2019-08-15 | 再開されました | Raymond James | Mkt Perform |
| 2019-07-18 | 開始されました | Deutsche Bank | Buy |
| 2019-05-23 | 再開されました | Goldman | Buy |
| 2019-04-03 | 開始されました | Morgan Stanley | Overweight |
| 2018-09-25 | 開始されました | Leerink Partners | Outperform |
| 2017-12-11 | 繰り返されました | Goldman | Buy |
すべてを表示
Blueprint Medicines Corp (BPMC) 最新ニュース
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Empirical Asset Management LLC Acquires Shares of 26,921 Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
JMP Securities Reaffirms Market Outperform Rating for Blueprint Medicines (NASDAQ:BPMC) - Defense World
FY2027 Earnings Estimate for BPMC Issued By Leerink Partnrs - Defense World
FY2027 Earnings Forecast for BPMC Issued By Leerink Partnrs - MarketBeat
Blueprint Medicines (NASDAQ:BPMC) vs. CV Sciences (OTCMKTS:CVSI) Financial Contrast - Defense World
Insider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) Director Sells 5,000 Shares of Stock - MarketBeat
Ariel Hurley Sells 2,250 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock - MarketBeat
Blueprint Medicines officer Hurley Ariel sells $225,000 in stock By Investing.com - Investing.com South Africa
Blueprint Medicines director Jeffrey Albers sells $511,400 in stock - Investing.com
Blueprint Medicines' SWOT analysis: stock surges on Ayvakit success - Investing.com
Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy - MSN
Blueprint Medicines (NASDAQ:BPMC) Shares Gap UpTime to Buy? - MarketBeat
Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines - Yahoo Finance
Blueprint Medicines Corporation Updates Corporate Presentation at J.P. Morgan Healthcare Conference - Defense World
Blueprint Medicines (BPMC) Stock Jumps 18.2%: Will It Continue to Soar? - Yahoo Finance
Blueprint Medicines’ (BPMC) Buy Rating Reaffirmed at Needham & Company LLC - Defense World
Blueprint Medicines (NASDAQ:BPMC) Receives “Outperform” Rating from Wedbush - Defense World
Blueprint Medicines shares surge on growth strategy and upbeat trial data - Investing.com
Blueprint Medicines Highlights 2024 Achievements and Future Growth - TipRanks
Blueprint Medicines Surges Over 10% as 2025 Growth Strategy Ignites Investor - Yahoo Finance
Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday - Benzinga
Blueprint Medicines' (BPMC) Outperform Rating Reiterated at Wedbush - MarketBeat
Blueprint Medicines (NASDAQ:BPMC) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth - PR Newswire
Diversified Trust Co Sells 8,258 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
NUT Midline Carcinoma Treatment Market Research Report 2023-2024 & 2034: Market Forecast by Treatment, Route of Administration, and End-User Across 5 Regions and 17+ Countries - GlobeNewswire Inc.
Blueprint Medicines (NASDAQ:BPMC) Stock Price Up 5.7%Still a Buy? - MarketBeat
Stifel maintains Buy rating and $155 target on Blueprint Medicines stock - Investing.com
Korea's only RET inhibitor, Retevmo, seeks insurance coverage again - KBR
Principal Financial Group Inc. Has $1.02 Million Holdings in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Principal Financial Group Inc. Sells 47,153 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Receives $123.33 Consensus Target Price from Brokerages - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Blueprint Medicines’ (BPMC) “Overweight” Rating Reaffirmed at Stephens - Defense World
What Analysts Are Saying About Blueprint Medicines Stock - Benzinga
Blueprint Medicines (NASDAQ:BPMC) Receives Overweight Rating from Stephens - MarketBeat
Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024 - Quantisnow
Sanctuary Advisors LLC Invests $202,000 in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines to Present at Upcoming Investor Conferences - Longview News-Journal
First Week of BPMC February 2025 Options Trading - Nasdaq
Blueprint Medicines director Jeffrey Albers sells $1.35 million in stock By Investing.com - Investing.com Australia
Blueprint Medicines director Jeffrey Albers sells $1.35 million in stock - Investing.com India
Insider Sell: Christina Rossi Sells Shares of Blueprint Medicines Corp (BPMC) - GuruFocus.com
Blueprint Medicines COO Christina Rossi sells $218,098 in shares By Investing.com - Investing.com Australia
Blueprint Medicines COO Christina Rossi sells $218,098 in shares - Investing.com
Blueprint Medicines Co. (NASDAQ:BPMC) Director Jeffrey W. Albers Sells 15,000 Shares - MarketBeat
Insider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) COO Sells 2,274 Shares of Stock - MarketBeat
Blueprint Medicines' SWOT analysis: stock's potential in precision oncology By Investing.com - Investing.com Australia
Blueprint Medicines (NASDAQ:BPMC) Shares Down 3.6%What's Next? - MarketBeat
Blueprint Medicines Corporation Seeks Validation of 2024 Stockholder Actions Through Section 205 Action - Defense World
Blueprint Medicines Corp (BPMC) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):